• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by Applied Molecular Transport Inc.

    1/9/24 6:12:27 AM ET
    $AMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMTI alert in real time by email
    15-12G 1 amti20240108_1512g.htm FORM 15-12G amti20240108_1512g.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     


     

    FORM 15

     


     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

     

    Commission File Number: 001-39306

     

    APPLIED MOLECULAR TRANSPORT INC.

    (Exact name of registrant as specified in its charter)

     

    6714 NW 16th Street, Suite B

    Gainesville, Florida 32653

    (386) 418-8060

    (Address, including zip code, and telephone number, including area code,

    of registrant’s principal executive offices)

     

    Common Stock, par value $0.0001 per share

    (Title of each class of securities covered by this Form)

     

    None

    (Titles of all other classes of securities covered by this Form)

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

     

    Rule 12g-4(a)(1)

    ☒

     
      Rule 12g-4(a)(2) ☐  
     

    Rule 12h-3(b)(1)(i)

    ☒

     
     

    Rule 12h-3(b)(1)(ii)

    ☐

     
     

    Rule 15d-6

    ☐

     
      Rule 15d-22(b) ☐  

     

    Approximate number of holders of record as of the certification or notice date: 1

     

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, Applied Molecular Transport Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

     

    APPLIED MOLECULAR TRANSPORT INC.

     

     

     

     

     

    Date: January 9, 2024

    By:

    /s/ N. Scott Fine

     

     

    Name:

    N. Scott Fine

     

     

    Title:

    Chief Executive Officer

     

     

     
    Get the next $AMTI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMTI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AMTI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.

      Combined company operating as Cyclo Therapeutics with primary focus on advancing Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) Cash runway extended into 2H 2024 with approximately $11.0 million cash on hand to fund operations Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, and Applied Molecular Transport Inc. (NASDAQ:AMTI) ("AMT"), a biopharmaceutical company, announced today the closing of its previously announced transaction pursuant to which AMT will merge with Cyclo Therape

      12/27/23 4:15:00 PM ET
      $AMTI
      $CYTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Cyclo Therapeutics Reports Third Quarter 2023 Financial Results

      Strong pace of enrollment continues in pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 ("NPC1") Merger with Applied Molecular Transport, Inc. ("AMT") on track to close before year end Company continues to bolster cash position to extend runway through clinical and regulatory milestones Cyclo Therapeutics, Inc. (NASDAQ:CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the third quarter 2023. "Our number one priority remains to

      11/15/23 8:05:00 AM ET
      $AMTI
      $CYTH
      $RFL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Real Estate
    • Applied Molecular Transport Reports Third Quarter 2023 Financial Results

      Company Entered into Definitive Merger Agreement with Cyclo Therapeutics Cash and Cash Equivalents of $18.1 million, as of September 30, 2023 SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (NASDAQ:AMTI) (AMT), a biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2023. Recent Business Highlights and Anticipated Milestones Entered into a definitive merger agreement with Cyclo Therapeutics Combined company will operate as Cyclo Therapeutics with primary focus on advancing Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1)The merger is expected to close by year end 20

      11/9/23 4:01:00 PM ET
      $AMTI
      Biotechnology: Pharmaceutical Preparations
      Health Care